TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25888828
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care intervention (test groups)
Study: 25888828
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care intervention (test 1 group)
Study: 25888828
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care intervention (test 2 group)
Study: 24004621
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SRP and occlusal adjustment
Study: 19178509
Drug: GIP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIP infusion at a rate of 2 pmol/kg/min for 4 h
Study: 19178509
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion for 4 h
Study: 19178509
Drug: GLP‐1 infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP‐1 infusion at a rate of 1 pmol/kg/min for 4 h
Study: 19178509
Drug: Ad libitum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad libitum energy intake after all four infusions
Study: 17102935
Drug: Intervention not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention not specified, but involves three treatments for borderline personality disorder (BPD).
Study: 11032702
Drug: NN703 (tabimorelin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NN703 (tabimorelin) 6.0 mg/kg
Study: 11032702
Drug: NN703 (tabimorelin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NN703 (tabimorelin) 12.0 mg/kg
Study: 11032702
Drug: NN703 (tabimorelin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NN703 (tabimorelin) 1.5 mg/kg
Study: 8339398
Drug: Scopolamine (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (low doses, transdermal patch)
Study: 3555041
Drug: Ciprofloxacin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (750 mg orally every 12 hours)
Study: 3555041
Drug: Cefotaxime (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (2.0 g intravenously every 8 hours)
Study: 25569408
Drug: Rectal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal ketamine (0.5 mg/kg)
Study: 25569408
Drug: Local peritonsillar
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local peritonsillar ketamine (2 mg/kg)
Study: 25569408
Drug: IV tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV tramadol hydrochloride (2 mg/kg)
Study: 22321929
Drug: Acute hypervolemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute hypervolemic hemodilution (AHH) with 6% hydroxyethyl starch solution at 24 ml×kg(‐1)×h(‐1)
Study: 22321929
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving compound electrolyte solution at 6 ml×kg(‐1)×h(‐1)
Study: 18339727
Drug: Occupational Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational Therapy (OT) - six home treatment sessions over 2 months
Study: 11977294
Drug: Glucose-insulin-kalium (GIK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-kalium (GIK) mixture
Study: 11977294
Drug: Placebo (physiological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (physiological saline infusion)
Study: 9042978
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily after initial 1-week triple therapy
Study: 9042978
Drug: Placebo after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo after initial 1-week triple therapy
Study: 9042978
Drug: 1-week low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-week low-dose triple therapy (omeprazole 20 mg b.d., clarithromycin 250 mg b.d., metronidazole 400 mg b.d.)
Study: 9042978
Drug: 1-week low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-week low-dose triple therapy
Study: 2829958
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of fish oil daily containing approximately 1.8 g eicosapentaenoic acid
Study: 21470751
Drug: Preoperative amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative amoxicillin
Study: 21470751
Drug: Postoperative amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative amoxicillin
Study: 16671837
Drug: Instructional music
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Instructional music therapy
Study: 16671837
Drug: Both music
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both music therapy treatment groups
Study: 12577332
Drug: Combined transdermal
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined transdermal acupoint electric stimulation (TAES) and isoflurane anesthesia
Study: 9225334
Drug: Dietary advice
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary advice and protein-rich supplements
Study: 27008542
Drug: D. pteronyssinus
Normalized name: D. farinae extract 6 SQ-HDM / D. pteronyssinus extract 6 SQ-HDM Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: D. pteronyssinus subcutaneous allergen immunotherapy (DP-AIT) for 24 months
Study: 27008542
Drug: D. pteronyssinus
Normalized name: D. farinae extract 6 SQ-HDM / D. pteronyssinus extract 6 SQ-HDM Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: D. pteronyssinus subcutaneous allergen immunotherapy (DP-AIT)
Study: 20470379
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 20 mg/day orally for 2 years
Study: 9856522
Drug: Intradermal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccination (5 injections of 20 microg each)
Study: 9856522
Drug: Subcutaneous vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous vaccination
Study: 7751414
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion (CSI) of octreotide
Study: 7751414
Drug: Intermittent subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent subcutaneous injection (ISI) of octreotide
Study: 2236455
Drug: Mirtazapine (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (18 mg)
Study: 2236455
Drug: Amitriptyline (111
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (111 mg)
Study: 280956
Drug: Chlorhexidine mouthwash
Normalized name: chlorhexidine Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine mouthwash (10 ml at 0.1%)
Study: 12375796
Drug: Irinotecan in
Normalized name: irinotecan Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan in combination with radiation therapy
Study: 31537189
Drug: Intravenous glibenclamide
Normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous glibenclamide
Study: 26376822
Drug: Punch biopsies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Punch biopsies with recall for treatment if CIN2/3 confirmed
Study: 24989152
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy informed psychotherapy (CBT-ip) only
Study: 24989152
Drug: CBT-ip with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-ip with medication (sertraline)
Study: 24989152
Drug: Medication (sertraline)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (sertraline) only
Study: 18029489
Drug: Almonds (84
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almonds (84 g daily for 4 weeks)
Study: 18029489
Drug: Pork (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pork (120 g daily for 4 weeks)
Study: 16148184
Drug: Antibodies in
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies in lymphocyte supernatant (ALS) assay
Study: 16148184
Drug: Antibody‐secreting cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody‐secreting cell (ASC) assay
Study: 8777097
Drug: Continuous i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous i.v. infusion of insulin (1.25 u. h‐1) (Group B)
Study: 8777097
Drug: Insulin 10
Normalized name: Human regular insulin 100 unit/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin 10 u. i.v. boluses every 2 h (Group C)
Study: 29427697
Drug: Barriers to
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barriers to medication adherence
Study: 16265344
Drug: Raltitrexed-oxaliplatin (arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltitrexed-oxaliplatin (arm A): raltitrexed 3 mg m(‐2) followed by oxaliplatin 130 mg m(‐2) on day 1, repeated every 3 weeks
Study: 16265344
Drug: Raltitrexed-irinotecan (arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltitrexed-irinotecan (arm B): CPT‐11 350 mg m(‐2) followed by raltitrexed 3 mg m(‐2), repeated every 3 weeks
Study: 10200809
Drug: Twice-weekly, six-month
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly, six-month progressive walking programme
Study: 2357134
Drug: Long peritoneal
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long peritoneal lavage (LPL) for 7 days compared to other treatments
Study: 2357134
Drug: Other treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other treatments (without lavage or lavage for 2 to 4 days)
Study: 395629
Drug: Cimetidine, 400
Normalized name: Cimetidine, 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 400 mg at night
Study: 31282006
Drug: liraglutide (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide (3.0 mg)
Study: 24372992
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 mg day(‐1)
Study: 24372992
Drug: Aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300 mg day(‐1)
Study: 24372992
Drug: Aspirin 3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 3.6 g day(‐1)
Study: 19605528
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein isolate (SPI) (80 mg/d aglycone isoflavones)
Study: 17478338
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lutein plus vitamins, minerals, and antioxidants
Study: 15669556
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE) vaginal cream (0.625 mg/g) applied once daily on days 1-21 of two 28-day cycles
Study: 7599569
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CY) 4 g/m2 alone
Study: 7599569
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CY) 4 g/m2 followed by GM‐CSF 250 micrograms/m2 or G‐CSF 600 micrograms
Study: 7599569
Drug: Post-transplant ANC
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-transplant ANC > = 500 x 10(6)/l
Study: 7599569
Drug: Post-transplant platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-transplant platelet count > = 50 x 10(6)/l
Study: 28101704
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CON) - 17.2 kJ gross energy/g diet
Study: 28101704
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein group (HP) - 19.4 kJ gross energy/g diet
Study: 28101704
Drug: High fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fat group (HF) - 19.9 kJ gross energy/g diet
Study: 28101704
Drug: High carbohydrate
Normalized name: High carbohydrate food
Approvals — FDA: no, EMA: no, PMDA: no
Description: High carbohydrate group (HC) - 19.1 kJ gross energy/g diet
Study: 27647058
Drug: No nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No nicotine patches (usual care)
Study: 17312332
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (12 weekly injections, targeting hemoglobin levels between 120 and 140 g/L)
Study: 15142880
Drug: Timed-sequential induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timed-sequential induction (arm C)
Study: 9021439
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg tirilazad mesylate every 6 hours for 29 doses (6.0 mg/kg/day for 7 days)
Study: 9021439
Drug: 3.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg/kg tirilazad mesylate every 6 hours for 29 doses (12.0 mg/kg/day for 7 days)
Study: 9021439
Drug: 4.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 mg/kg tirilazad mesylate every 6 hours for 29 doses (16.0 mg/kg/day for 7 days)
Study: 1875538
Drug: ONO 3708
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO 3708 (2.5 micrograms.kg‐1.min‐1 given with continuous infusion)
Study: 1087137
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate once per month with citrovorum rescue for 3 months
Study: 1087137
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of methotrexate and immunization monthly for 3 months
Study: 1087137
Drug: Combination immunochemotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination immunochemotherapy
Study: 27979834
Drug: Ciclosporin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin 2.5 mg/kg as an intravenous injection after anaesthesia induction but before start of surgery
Study: 27979834
Drug: Placebo as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as an intravenous injection after anaesthesia induction but before start of surgery
Study: 27979834
Drug: Ciclosporin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin 2.5 mg/kg
Study: 21331635
Drug: Ozone treatment
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone treatment (60 s)
Study: 21331635
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ozone treatment)
Study: 19602718
Drug: TETA 100
Normalized name: TETA
DrugBank: Triethylenetetramine (DB06824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TETA 100 mg
Study: 19602718
Drug: TETA 300
Normalized name: TETA
DrugBank: Triethylenetetramine (DB06824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TETA 300 mg
Study: 19602718
Drug: TETA 600
Normalized name: TETA
DrugBank: Triethylenetetramine (DB06824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TETA 600 mg
Study: 19602718
Drug: TETA 1800
Normalized name: TETA
DrugBank: Triethylenetetramine (DB06824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TETA 1800 mg
Study: 15280678
Drug: Conventional cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cyclosporine triple therapy
Study: 96461
Drug: Ciclazindol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclazindol (100 mg/day)
Study: 31397184
Drug: TIO/FORMfixed (18/12
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIO/FORMfixed (18/12 µg once daily via Discair inhaler)
Study: 31397184
Drug: TIO/FORMbid (tiotropium
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIO/FORMbid (tiotropium 18 µg by Handihaler + formoterol 12 µg twice daily by Aerolizer)
Study: 31397184
Drug: TIOmono (tiotropium
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIOmono (tiotropium 18 µg by Handihaler)
Study: 17532101
Drug: PsA‐TT vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PsA‐TT vaccine (Group 1)
Study: 17532101
Drug: Meningococcal Polysaccharide
Normalized name: meningococcal polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal Polysaccharide Vaccine A+C (Group 2)
Study: 17532101
Drug: Tetanus Toxoid
Normalized name: Tetanus Toxoid
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetanus Toxoid Vaccine Adsorbed (Group 3)
Study: 14985695
Drug: Once-a-week 2800
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once-a-week 2800 microg folic acid supplement
Study: 14985695
Drug: Daily 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 400 microg folic acid supplement
Study: 7893272
Drug: Other silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other silymarin preparations
Study: 30693096
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation treatment alongside usual IAPT care
Study: 30693096
Drug: Usual IAPT
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual IAPT treatment alone
Study: 29927785
Drug: Intravenous zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zoledronic acid (ZOL) 5 mg annually for 2 years
Study: 29927785
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from tenofovir disoproxil fumarate (TDF) to another active antiretroviral drug
Study: 27239927
Drug: Clopidogrel 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 150 mg + ASA 300 mg (Subgroup 2)
Study: 27239927
Drug: ASA 300
Normalized name: ASA 300 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 300 mg + Ticagrelor 90 mg twice daily (Subgroup 3)
Study: 27239927
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg + ASA 300 mg (Subgroup 1)
Study: 25336097
Drug: Nasal saline
Normalized name: Nasal Saline
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal saline irrigation (isotonic and hypertonic solutions)
Study: 25336097
Drug: Nasal aspiration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal aspiration with isotonic saline solution
Study: 25336097
Drug: Isotonic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic and hypertonic saline solutions
Study: 20214777
Drug: Web-based self-help
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based self-help intervention based on Cognitive Behavioural Therapy (CBT)
Study: 8617554
Drug: Metronidazole 400
Normalized name: metronidazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 400 mg daily for 5 days
Study: 8617554
Drug: Metronidazole 7.5
Normalized name: metronidazole 7.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 7.5 mg/Kg thrice daily for 5 days
Study: 8617554
Drug: Metronidazole therapy
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole therapy
Study: 2765377
Drug: Tamoxifen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (10 mg or 20 mg)
Study: 26635296
Drug: Consensus messages
Normalized name: Consensi
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Consensus messages about vaccine safety (90% of medical scientists agree vaccines are safe)
Study: 18316547
Drug: Panitumumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panitumumab (6 mg/kg every other week)
Study: 10724054
Drug: Subset of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subset of 1034 patients with CAUTI (89 with >103 colony-forming units/mL)
Study: 8754444
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (group A)
Study: 8754444
Drug: No thrombolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No thrombolytic therapy (group B)
Study: 8754444
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy in patients with left ventricular dysfunction
Study: 8754444
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy in patients with symptom delay > 4 hours
Study: 24467369
Drug: Aripiprazole (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (0, 2 or 10 mg/day/p.o.)
Study: 22236488
Drug: Disease management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease management approach including systematic screening, treatment upon positive screening, monitoring, and intensified treatment in case of non-remission.
Study: 18346028
Drug: Artesunate plus
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate plus amodiaquine (ASAQ) - artesunate 4 mg/kg daily and amodiaquine 10 mg/kg daily for 3 days.
Study: 18346028
Drug: Artemether-lumefantrine (AL)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine (AL) - 5-14 kg: one tablet; 15-24 kg: two tablets; 25-34 kg: three tablets, twice daily for 3 days.
Study: 16259789
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 600 mg reduced glutathione per day
Study: 16259789
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 50 mg alpha‐lipoic acid per day
Study: 16259789
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 100 mg N‐acetylcysteine per day
Study: 16259789
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (ST) based on WHO recommendations